EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immune persistence up to one year after a single dose of pentavalent meningococcal ACYWX conjugate vaccine (NmCV-5) administered to children, adolescents and adults (2-29 years of age) in Mali and The Gambia

Lionel Martellet iD, Dhananjay Kapse, Prasad S Kulkarni, Ed Clarke, Magnus Ochoge, Ama Umesi, Milagritos Tapia, Samba Sow, Fadima Haidara, Fatoumata Diallo, Yuxiao Tang, Mark R Alderson und 4 weitere

Clinical Infectious Diseases · 13.11.2026

DOI: 10.1093/cid/ciag693 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 13.11.2026. Verfasst von Lionel Martellet und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Vaccine Innovation and Access, PATH, Genève, Switzerland. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A meningococcal ACYWX conjugate vaccine (NmCV-5) has been developed to address epidemic meningitis in Sub-Saharan Africa. During a phase 3 observer-blind clinical trial in 2- to 29-year-olds in Mali and The Gambia, a single dose of either NmCV-5 or a licensed quadrivalent ACYW conjugate vaccine (MenACYW-D) was found to be safe and immunogenic 28 days post-vaccination. Among the original 1800 study participants, a subset of 786 was further evaluated for immune responses by rabbit complement serum bactericidal assay (rSBA) at 6 and 12 months after immunization. At 12 months post-immunization, 100% of NmCV-5 group retained titers ≥128 for serogroups A, Y, and W, 99.8% for X and 90.9% for serogroup C. For the MenACYW-D group, 100% retained titers ≥128 for A, 99.6% for Y, 98.1% for W, 74.8% for serogroup C, and 89.9% for X. The seroresponse rate in the NmCV-5 group was 58% for A, 91.5% for Y, 96.4% for W, 82.6% for X and 89.8% for C. In the MenACYW-D group, the seroresponse rate was 37.6% for A, 86.1% for Y, 92.7% for W, 75.5% for C, and 7.1% for X. Geometric mean titers (GMTs) declined between 28 days and 12 months. At 12 months, in the NmCV-5 group they were at 985 for C and >4096 for all other serogroups. In the MenACYW-D group, GMTs were 269 for C, >2048 for A, W, Y and remained at baseline levels for X. Further investigation is needed at later timepoints to project NmCV-5 duration of protection.

Schlagwörter

Stichwörter der Autor:innen

ImmunogenicityMenFiveMeningococcalPersistenceVaccine

Autor:innen und Institutionen

  • Center for Vaccine Innovation and Access, PATH, Genève, Switzerland.
  • Serum Institute of India Pvt. Ltd., Pune, India.
  • Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine.
  • Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Centre pour les Vaccins en Développement, Mali, Bamako, Mali.
  • Center for Vaccine Innovation and Access, PATH, Seattle, Washington, USA.

ORCID-Profile: Lionel Martellet, Niranjan Bhat, Nancy Hosken

Zitieren

APA

Martellet, L., Kapse, D., Kulkarni, P. S., Clarke, E., Ochoge, M., Umesi, A., Tapia, M., Sow, S., Haidara, F., Diallo, F., Tang, Y., Alderson, M. R., Bhat, N., Welsch, J. A., Hosken, N., & LaForce, F. M. (2026). Immune persistence up to one year after a single dose of pentavalent meningococcal ACYWX conjugate vaccine (NmCV-5) administered to children, adolescents and adults (2-29 years of age) in Mali and The Gambia. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag693

Vancouver

Martellet L, Kapse D, Kulkarni PS, Clarke E, Ochoge M, Umesi A, et al. Immune persistence up to one year after a single dose of pentavalent meningococcal ACYWX conjugate vaccine (NmCV-5) administered to children, adolescents and adults (2-29 years of age) in Mali and The Gambia. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag693

BibTeX
@article{Martellet2026,
  author = {Martellet, Lionel and Kapse, Dhananjay and Kulkarni, Prasad S and Clarke, Ed and Ochoge, Magnus and Umesi, Ama and Tapia, Milagritos and Sow, Samba and Haidara, Fadima and Diallo, Fatoumata and Tang, Yuxiao and Alderson, Mark R and Bhat, Niranjan and Welsch, Jo Anne and Hosken, Nancy and LaForce, F Marc},
  title = {Immune persistence up to one year after a single dose of pentavalent meningococcal ACYWX conjugate vaccine (NmCV-5) administered to children, adolescents and adults (2-29 years of age) in Mali and The Gambia},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciag693}
}
Kostenlos starten →